全文获取类型
收费全文 | 38271篇 |
免费 | 2903篇 |
国内免费 | 63篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 1816篇 |
妇产科学 | 626篇 |
基础医学 | 8324篇 |
口腔科学 | 207篇 |
临床医学 | 5171篇 |
内科学 | 12662篇 |
皮肤病学 | 533篇 |
神经病学 | 857篇 |
特种医学 | 257篇 |
外科学 | 2553篇 |
综合类 | 240篇 |
现状与发展 | 2篇 |
一般理论 | 9篇 |
预防医学 | 4835篇 |
眼科学 | 148篇 |
药学 | 1768篇 |
中国医学 | 35篇 |
肿瘤学 | 1092篇 |
出版年
2023年 | 1642篇 |
2022年 | 1803篇 |
2021年 | 2407篇 |
2020年 | 2621篇 |
2019年 | 1504篇 |
2018年 | 1518篇 |
2017年 | 1566篇 |
2016年 | 1462篇 |
2015年 | 1636篇 |
2014年 | 2415篇 |
2013年 | 1852篇 |
2012年 | 1762篇 |
2011年 | 1700篇 |
2010年 | 1688篇 |
2009年 | 1575篇 |
2008年 | 1207篇 |
2007年 | 1361篇 |
2006年 | 1217篇 |
2005年 | 1172篇 |
2004年 | 1106篇 |
2003年 | 1006篇 |
2002年 | 1021篇 |
2001年 | 1066篇 |
2000年 | 857篇 |
1999年 | 832篇 |
1998年 | 504篇 |
1997年 | 287篇 |
1996年 | 321篇 |
1995年 | 112篇 |
1994年 | 99篇 |
1993年 | 77篇 |
1992年 | 230篇 |
1991年 | 215篇 |
1990年 | 185篇 |
1989年 | 172篇 |
1988年 | 189篇 |
1987年 | 81篇 |
1986年 | 30篇 |
1985年 | 96篇 |
1984年 | 81篇 |
1983年 | 46篇 |
1982年 | 69篇 |
1981年 | 54篇 |
1980年 | 48篇 |
1979年 | 46篇 |
1978年 | 54篇 |
1977年 | 35篇 |
1976年 | 39篇 |
1974年 | 31篇 |
1973年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
2.
3.
4.
《Clinical therapeutics》2022,44(3):403-417.e6
PurposeEntecavir (ETV) and tenofovir disoproxil fumarate (TDF) are both recommended as first-line treatments for patients with chronic hepatitis B virus (CHB) infection according to international HBV treatment guidelines. However, recent studies reported conflicting results regarding the preferred antiviral in the prevention of hepatocellular carcinoma (HCC). This cohort study aimed to investigate this issue by using Taiwan's National Health Insurance Research Database, wherein a “finite” but not life-long treatment policy was applied.MethodsFrom January 2008 to December 2013, a total of 12,388 consecutive adult patients with CHB who received a finite course of TDF treatment (n = 1250) or ETV treatment (n = 11,138) were analyzed through screening for study eligibility followed by the 1:4 propensity score matching method.FindingsIn the entire cohort, the annual incidence and survival between the ETV and TDF groups were not significantly different regarding HCC occurrence (2.05 vs 2.74 per 100 patient-years [PY]; P = 0.055; hazard ratio [HR], 0.975; log-rank, P = 0.966), cirrhosis-related complications (1.9 vs 2.4 per 100 PY; P = 0.149; HR, 0.869; log-rank, P = 0.388), or all-cause mortality (2.16 vs 1.6 per 100 PY; P = 0.119; HR, 0.831; log-rank, P = 0.342), respectively. Propensity score matching analyses yielded similar results regarding HCC occurrence, cirrhosis-related complications, and all-cause mortality. In addition, these findings were consistently reproduced in the subgroups of patients with chronic hepatitis and cirrhosis that developed before antiviral treatment.ImplicationsETV and TDF did not significantly differ in prevention of HCC occurrence or reduction of cirrhosis-related complications and all-cause mortality in patients with CHB receiving a finite period of treatment. 相似文献
5.
《Clinical therapeutics》2022,44(12):1604-1623
PurposeVoriconazole, an antifungal drug, is metabolized by a cytochrome P450 isozyme. Increased adverse effects are observed in Asians because of the high rate of poor metabolizers. In this therapeutic drug monitoring (TDM) guideline, recommendations were made according to ethnic group.MethodsFive clinical questions were used. For the preparation of the guideline, the performance of TDM in multicenter studies was surveyed (study 1). We also conducted a systematic review and meta-analysis (study 2) to establish recommendations for non-Asians and Asians.FindingsIn study 1, 401 patients were surveyed. A risk of supratherapeutic concentrations was found in Japanese patients who adhered to the recommended dose. Target trough levels were achieved in 87% of patients with dose reductions. Although the trough level measured at the onset of adverse effects (AEs) was significantly associated with hepatotoxicity, no significant correlation was found between the initial trough level and hepatotoxicity, which indicated that hepatotoxicity was successfully prevented by the trough-guided dosing. In study 2, 22 studies (11 Asian locations and 11 non-Asian locations) were included in meta-analysis for the relationship between trough cutoff level (3, 4, 5, 5.5, and 6 µg/mL) and AEs. Significant differences were found for all cutoff levels, with the highest odds ratio for 4.0 µg/mL in Asian locations. In contrast, in non-Asian locations, no more than 1 study was available for any trough cutoff level, except for 5.5 µg/mL, at which level a significant increase in AEs was found. These findings indicate that TDM is strongly recommended to prevent AEs in Asians, and TDM is generally recommended for non-Asians to address subtherapeutic concentrations. TDM on day 3 is recommended to assess pharmacokinetic properties, including loading and maintenance doses. If the patient condition permits, delaying until day 5 is suggested for Asians because of the prolonged t½ in poor metabolizers. A trough level ≥1.0 µg/mL is strongly recommended to improve efficacy. Trough levels ≥2.0 µg/mL are suggested for invasive aspergillosis. To decrease adverse effects, trough levels <4.0 µg/mL are strongly recommended in Asians, whereas trough levels <5.5 µg/mL are generally recommended in non-Asians. Maintenance doses of 4 and 3 mg/kg twice daily are recommended in non-Asians and Asians, respectively.ImplicationsDifferent indications, timings, and target trough levels for TDM and different regimens are suggested for Asians and non-Asians. 相似文献
6.
Clinical characteristics of pediatric patients with COVID-19 between Omicron era vs. pre-Omicron era
《Journal of infection and chemotherapy》2022,28(11):1501-1505
IntroductionDetailed data on clinical characteristics in children with the omicron strain of SARS-COV-2 are limited.MethodsWe conducted a retrospective observational study of children with COVID-19 at the National Center for Child Health and Development to evaluate the clinical manifestations during and before the emergence of the omicron variant. Only symptomatic patients without underlying diseases were included. Participants were divided into two temporal groups: the “omicron era” (1/2022–2/2022) and the “pre-omicron era,” where the delta variant predominated (7/2021–11/2021). The patients were subclassified into an older vaccine-eligible group (aged 12–17 years), a younger vaccine-eligible group (aged 5–11 years), and a vaccine-ineligible group (aged 0–4 years).ResultsWe compared 113 patients in the omicron era with 106 in the pre-omicron era. Most patients in both eras had non-severe disease, and no patients required mechanical ventilation or died. Among patients aged 0–4 years, sore throat and hoarseness were more common during the omicron era than the pre-omicron era (11.1% vs. 0.0% and 11.1% vs. 1.5%, respectively). Croup syndrome was diagnosed in all patients with hoarseness. Among patients aged 5–11 years, vomiting was more frequent during the omicron era (47.2%) than during the pre-omicron era (21.7%). Cough and rhinorrhea were less common during the omicron era in patients aged 0–4 and 5–11 years, respectively, than during the pre-omicron era.ConclusionsIn children with COVID-19, clinical manifestations differed between the omicron and pre-omicron eras. In the Omicron era, croup syndrome was more frequent in vaccine-ineligible children. 相似文献
7.
8.
9.
10.
《Clinical Microbiology Newsletter》2022,44(22):199-208
Monkeypox virus (MPXV) has garnered recent attention as outbreaks are continually reported outside historic regions of endemicity in Africa. Consequently, MPXV is becoming routinely included in the differential diagnosis of rash illnesses, requiring clinicians and laboratorians alike to quickly adapt to a new public health emergency. This review discusses the epidemiology, clinical presentation, and laboratory testing of MPXV in the context of recent outbreaks. 相似文献